Company Profiles

driven by the PitchBook Platform

Alethia Biotherapeutics

Description

Developer of monoclonal antibody therapeutics intended to novel clinically relevant targets identification. The company's monoclonal antibody therapeutics develops patented STAR discovery technology as well as focuses on invasive carcinomas and cancer-associated epithelial-to-mesenchymal transition, providing the healthcare professionals with therapeutics for the treatment of cancer and cancer-associated complications.

2002

Founded

PRIVATE

Status

11-50

Employees

2ndary - Private

Latest Deal Type

$16.4M

Total Amount Raised

4

Investors

Description

Developer of monoclonal antibody therapeutics intended to novel clinically relevant targets identification. The company's monoclonal antibody therapeutics develops patented STAR discovery technology as well as focuses on invasive carcinomas and cancer-associated epithelial-to-mesenchymal transition, providing the healthcare professionals with therapeutics for the treatment of cancer and cancer-associated complications.

Website:

www.alethiabio.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

141, President-Kennedy Avenue Suite SB-5100 Montreal, Quebec H2X 1Y4Canada +1 (514) 858-7666
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Alethia Biotherapeutics's full profile, request a free trial.

    Alethia Biotherapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Alethia Biotherapeutics Investors (4)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    CellscriptCorporationMinority000 0000000 0000
    Epicentre TechnologiesVC-Backed CompanyMinority000 0000000 0000
    GeneChem ManagementVenture CapitalMinority000 0000000 0000
    IBC GeneriumOtherMinority000 0000000 0000
    Cellscript Corporation
    Epicentre Technologies VC-Backed Company
    GeneChem Management Venture Capital
    IBC Generium Other

    Alethia Biotherapeutics Executive Team (4)

    NameTitleBoard
    Seat
    Contact
    Info
    Yves CornellierPresident, Chief Executive Officer and Board Member
    Mario Filion Ph.DExecutive Vice President & Chief Scientific Officer
    Julie Laurin Ph.DDirector, Preclinical Drug Development
    Jacques JolivetChief Medical Officer
    Yves Cornellier President, Chief Executive Officer and Board Member
    Mario Filion Ph.D Executive Vice President & Chief Scientific Officer
    Julie Laurin Ph.D Director, Preclinical Drug Development
    Jacques Jolivet Chief Medical Officer

    Alethia Biotherapeutics Board Members (1)

    NameRepresentingRoleSinceContact
    Info
    Elizabeth Douville Ph.DGeneChem ManagementGeneral Partner000 0000
    Elizabeth Douville Ph.D General Partner GeneChem Management
    Request full access to PitchBook